NYSE$ABT

Abbott Laboratories · Q2 2020 earnings

Q2 2020 earnings · · Investor relations

Briefing

Abbott's Q2 2020 results were announced, exceeding analysts' expectations.

Abbott's Q2 2020 worldwide sales reached $7.3 billion, a decrease of 8.2 percent on a reported basis but only a 5.4 percent decrease on an organic basis. The company's diversified business model and leadership in COVID-19 testing contributed to significant improvements in growth trends throughout the quarter.

  • Worldwide sales decreased 8.2 percent on a reported basis and 5.4 percent on an organic basis.
  • Nutrition sales increased 0.4 percent on a reported basis and 3.1 percent on an organic basis.
  • Diagnostics sales increased 4.7 percent on a reported basis and 7.1 percent on an organic basis, driven by COVID-19 testing.
  • Medical Devices sales decreased 21.2 percent on a reported basis and 19.9 percent on an organic basis due to reduced procedure volumes.

Headline financials

Total Revenue

$7.33B

Previous: $7.98B-8.2%
EPS (adj)

$0.57

Previous: $0.82-30.5%
Capital Expenditures

-$1B

Previous: -$803M-24.8%
Free Cash Flow

-$465M

Previous: $203M-329.1%
Net Income

$537M

Previous: $1.01B-46.6%
Operating Income

$672M

Previous: $1.21B-44.3%
Gross Profit

$4.07B

Previous: $4.7B-13.5%
Cash & Equivalents

$4.76B

Previous: $3.14B+51.8%
Total Assets

$68.8B

Previous: $68.4B+0.5%
Stock-Based Comp

$115M

Previous: $114M+0.9%

Revenue & EPS history

Abbott · Revenue · Quarterly

$7.33B

Q2 2020-8.2%vs Q2 2019
Beat estimate in 15 of 16 quarters(94%)
ActualEstimate

Revenue by segment

Abbott · $6.7B total across 2 segments · Q3 2023

  • Medical Devices
    $4.25B+17.5%
  • Diagnostics
    $2.45B-33.3%

Forward guidance

Abbott projects full-year 2020 diluted earnings per share from continuing operations under GAAP of at least $2.00. Excluding specified items, projected adjusted diluted earnings per share from continuing operations would be at least $3.25 for full-year 2020.

Historical earnings impact

How earnings announcements have historically affected this stock's price.

Avg. return before/after earnings

Based on 20 quarterly earnings reports · overlaid with Q2 2020

Historical avgQ2 2020

+0.6%

Avg return

Earnings day

+0.7%

Avg return

5 days after

+1.1%

Avg return

30 days after

61%

45 / 74 earnings

Positive

+10.3%

Q3 2013

Best reaction

-9.9%

Q4 2025

Worst reaction

Earnings price reactions
QuarterReport dateReaction (Day 0)+5 days+30 days
Q1 2026-0.2%-8.7%-16.8%
Q4 2025-9.9%-10.3%-7.1%
Q3 2025-2.9%-2.8%-2.0%
Q2 2025-0.1%+1.4%+3.3%
Q1 2025+2.8%+2.9%+6.8%
Q4 2024+0.8%+10.8%+15.5%
Q3 2024+1.6%+0.8%-0.1%
Q2 2024-2.5%-0.7%+6.0%
Q1 2024-3.6%-2.0%-4.7%
Q4 2023-1.4%-0.5%+4.8%
Q3 2023+3.6%+4.0%+8.0%
Q2 2023+6.5%+5.3%-3.3%
Q1 2023+6.0%+6.0%+4.6%
Q4 2022-1.3%-2.4%-10.7%
Q3 2022-9.3%-6.4%-1.1%
Q2 2022+0.7%-1.3%+0.1%
Q1 2022+2.8%+0.0%-5.6%
Q4 2021-2.3%+3.4%-0.7%
Q3 2021+4.8%+6.1%+6.3%
Q2 2021+1.5%+0.7%+6.2%
Q1 2021-1.5%-1.0%-5.4%
Q4 2020+4.9%+6.8%+4.4%
Q3 2020+1.0%+0.6%+2.3%
Q2 2020+2.6%+1.5%+3.4%
Q1 2020+5.6%+3.4%-1.2%
Q4 2019+1.1%-0.2%-2.5%
Q3 2019+0.5%-0.4%+4.5%
Q2 2019+5.5%+5.9%+1.9%
Q1 2019-3.2%-2.4%-0.5%
Q4 2018-0.9%-3.4%+6.5%
Q3 2018-4.0%-3.4%+1.5%
Q2 2018+1.6%+0.6%+3.1%
Q1 2018+0.1%-1.6%+3.2%
Q4 2017+6.7%+6.9%+0.8%
Q3 2017+1.7%+1.9%+0.9%
Q2 2017+2.9%+2.8%-1.4%
Q1 2017+1.3%+1.6%-0.6%
Q4 2016+1.6%+1.6%+12.5%
Q3 2016-1.0%-1.8%-3.2%
Q2 2016+3.0%+3.9%+5.8%
Q1 2016+0.1%
Q4 2015-6.5%
Q3 2015+4.2%
Q2 2015+2.9%
Q1 2015+2.8%
Q4 2014+3.1%
Q3 2014+0.1%
Q2 2014+1.8%
Q1 2014+2.5%
Q4 2013-4.3%
Q3 2013+10.3%
Q2 2013+0.0%
Q1 2013+1.3%
Q4 2012-0.3%
Q3 2012-7.6%
Q2 2012-1.0%
Q1 2012-1.5%
Q4 2011-0.2%
Q3 2011-0.4%
Q2 2011-0.1%
Q1 2011+0.9%
Q1 2008+1.4%
Q4 2010+1.4%
Q3 2010-0.8%
Q2 2010+0.7%
Q1 2009-1.4%
Q1 2010+0.9%
Q4 2007-1.1%
Q4 2009-1.1%
Q3 2008+1.4%
Q3 2009+1.4%
Q2 2009+2.1%
Q4 2008+2.1%
Q2 2008+2.1%

Discussion

Share your read of this quarter. Sign-in carries your eToro identity.

Join the conversation

Sign in with eToro to post your read of this quarter and vote on others'.

Sign in with eToro